Literature DB >> 2874967

Discriminative stimulus properties of phenylisopropylamine derivatives.

R A Glennon.   

Abstract

The phenylisopropylamine unit is a common structural fragment amongst many centrally-acting agents. However, these agents do not necessarily produce similar behavioral effects in test subjects. For example, the phenylisopropylamine derivative amphetamine is a central nervous system (CNS) stimulant whereas its 2,5-dimethoxy-4-methyl analog, i.e. DOM, is considered to be a hallucinogen. Employing animals trained to discriminate either (+)-amphetamine or (+/-)-DOM from saline in a two-lever operant procedure, stimulus generalization studies were conducted to evaluate members of a series of methoxy-substituted, and related, phenylisopropylamines. In this manner, it was possible to classify these agents as to which produced amphetamine-like effects, and which produced DOM-like effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874967     DOI: 10.1016/0376-8716(86)90003-7

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

1.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys.

Authors:  Douglas A Smith; Bruce E Blough; Matthew L Banks
Journal:  Psychopharmacology (Berl)       Date:  2016-10-05       Impact factor: 4.530

3.  The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.

Authors:  Richard A Glennon
Journal:  J Med Chem       Date:  2017-03-15       Impact factor: 7.446

Review 4.  Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention.

Authors:  Richard A Glennon
Journal:  Adv Pharmacol       Date:  2014

5.  Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.

Authors:  M A Nader; S M Hoffmann; J E Barrett
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

7.  Discriminative stimulus effects of N,N-diisopropyltryptamine.

Authors:  Theresa M Carbonaro; Michael J Forster; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2012-10-16       Impact factor: 4.530

Review 8.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

9.  3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors.

Authors:  R A Lyon; R A Glennon; M Titeler
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 10.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.